A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator ...
Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug ...
Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...
The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive ...
U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved the company’s non-opioid pain treatment.
Vertex has gained the FDA's approval for its nonaddictive pain med Journavx, which becomes the first significant innovation ...
Approval of Journavx for acute pain marks the first new class of acute pain medication approved by the FDA in over 20 years.
The Food and Drug Administration announced Thursday its approval of suzetrigine, the first new painkiller greenlit by the ...